NCT03937648View on ClinicalTrials.gov

Study to Evaluate Pharmacokinetics, Safety, and Tolerability Ildong COL-144 Tablet in Korean Healthy Volunteers

PHASE1UnknownINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

October 31, 2019

Study Completion Date

December 31, 2019

Conditions
Healthy
Interventions
DRUG

COL-144 50mg

COL-144 50mg

DRUG

COL-144 100mg

COL-144 100mg

DRUG

COL-144 200mg

COL-144 200mg

DRUG

COL-144 400mg

COL-144 400mg

DRUG

Placebo

Placebo

Sponsors
All Listed Sponsors
lead

IlDong Pharmaceutical Co Ltd

INDUSTRY

NCT03937648 - Study to Evaluate Pharmacokinetics, Safety, and Tolerability Ildong COL-144 Tablet in Korean Healthy Volunteers | Biotech Hunter | Biotech Hunter